Published

Study Protocol for “Exploring the safety and therapeutic potential of psilocybin in the treatment of anorexia nervosa in adolescents and young adults”

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: PLOS One
Date: 2026-06-30
Source: Crossref
DOI: 10.1371/journal.pone.0352246
PubMed: 42378255

Authors

Sjöström David Schau Rybäck Olea Claesdotter Knutsson Emma Kajonius Petri Jensen Sondén Oskar Carlbring Per Björkstrand Johannes Movahed Rad Pouya

Watch author

Derived topics and classifications

psilocybin Eating Disorders Brain Imaging Aging Wellbeing Personality Change Clinical Trial Randomized Controlled Trial Review Article Adolescents Safety Adverse Events Randomized Controlled Trial

Citation graph

40 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

10.1016/s0140-6736(20)30059-3 10.1097/yco.0000000000000739 10.1001/archgenpsychiatry.2011.74 10.1016/j.psychres.2015.09.008 10.1016/j.amjmed.2015.06.031 10.1186/s40337-024-01006-y 10.1097/yco.0000000000000453 10.1016/j.jpsychires.2023.01.002 10.1016/s2215-0366(15)00356-9 10.1016/s2215-0366(21)00038-9 10.1111/nyas.15314 10.1016/j.neubiorev.2024.105820

Indexed papers citing this DOI

Study Protocol for “Exploring the safety and therapeutic potential of psilocybin in the treatment of anorexia nervosa in adolescents and young adults”2026-06-30

Related papers

Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.Trials · 2024-05-21 Comparative Acute Effects of LSD, Psilocybin and Mescaline in a Random-Order Placebo-Controlled Cross-Over Study in Healthy SubjectsClinicalTrials.gov · 2024-01-24 A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)ClinicalTrials.gov · 2026-07-23 A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive DisorderClinicalTrials.gov · 2025-08-19 A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)ClinicalTrials.gov · 2024-08-15 Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression.Trials · 2024-07-03 Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial.Contemporary clinical trials · 2022-12-01